Use of XXXX in pediatric @entity358 : recent literature controversies.

@entity1 @entity796 @entity7646 @entity565 @entity25081 @entity5924 @entity358 @entity7187 @entity1576 @entity4595 @entity4154 @entity1577
OBJECTIVE: To review the mechanisms of action of @entity7187 in pediatric @entity1576 and their clinical indications. SOURCES: Review in the PubMed database, comprising the following terms in English: " @entity7646 and @entity565 "; " @entity7646 and @entity1577 "; " @entity7646 @entity5924 and viral acute"; " @entity7646 and @entity4154 " and " @entity7646 and non- @entity1577 @entity4595 ". SUMMARY OF THE FINDINGS: The spectrum of action of @entity7187 includes production of inflammatory mediators, control of mucus hypersecretion, and modulation of host-defense mechanisms. The potential benefit of @entity7646 antibiotics has been studied in a variety of @entity358 , such as @entity1577 ( @entity1577 ), @entity4595 , @entity565 , acute @entity5924 , and non- @entity1577 @entity4595 . Several studies have evaluated the benefits of @entity7187 in @entity565 refractory to therapy, but the results are controversial and indications should be limited to specific phenotypes. In @entity25081 , there is no consistent benefit in acute conditions, although recent data have shown an effect in recurrent wheezing prevention. In @entity1 with @entity1577 results are also contradictory, but the consensus states there is a small clinical benefit, especially for @entity1 infected with @entity796 . There was also no positive action of @entity7187 in @entity1 with post-infectious @entity4154 . @entity1 with non- @entity1577 @entity4595 seem to have clear benefits regarding the use of @entity7187 , which showed clinical advantages in parenchyma protection and lung function. CONCLUSIONS: The long-term use of @entity7187 should be limited to highly selected situations, especially in @entity1 with @entity4595 . Careful evaluation of the benefits and potential damage are tools for their indication in specific groups.
